Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lucid Diagnostics (LUCD) Common Equity (2021 - 2025)

Lucid Diagnostics' Common Equity history spans 5 years, with the latest figure at $10.9 million for Q4 2025.

  • For Q4 2025, Common Equity rose 102.86% year-over-year to $10.9 million; the TTM value through Dec 2025 reached $10.9 million, up 102.86%, while the annual FY2025 figure was $10.9 million, 102.86% up from the prior year.
  • Common Equity reached $10.9 million in Q4 2025 per LUCD's latest filing, down from $25.8 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $54.7 million in Q4 2021 to a low of -$24.1 million in Q3 2021.
  • Average Common Equity over 5 years is $12.3 million, with a median of $11.4 million recorded in 2024.
  • Peak YoY movement for Common Equity: surged 384.07% in 2022, then plummeted 145.21% in 2025.
  • A 5-year view of Common Equity shows it stood at $54.7 million in 2021, then crashed by 57.9% to $23.0 million in 2022, then plummeted by 110.03% to -$2.3 million in 2023, then soared by 333.28% to $5.4 million in 2024, then skyrocketed by 102.86% to $10.9 million in 2025.
  • Per Business Quant, the three most recent readings for LUCD's Common Equity are $10.9 million (Q4 2025), $25.8 million (Q3 2025), and $7.9 million (Q2 2025).